CLEVELAND--(BUSINESS WIRE)--July 6, 2006--Copernicus Therapeutics, Inc. announced that its non-viral based DNA nanoparticles technology can efficiently deliver even very large sizes of nucleic acid, up to at least 20,000 base pairs in size, to the lung cells of mice. Thus, Copernicus has again demonstrated the robust nature of its proprietary non-viral delivery system by successfully surmounting a significant limiting factor of competitive delivery technologies. These data were published in the July issue of the journal Gene Therapy.
